Entheon Biomedical Corp.
ENBI
CNSX
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -25.56% | -53.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.56% | -53.12% | |||
| Operating Income | 25.56% | 53.12% | |||
| Income Before Tax | 27.48% | 53.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.48% | 53.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.48% | 53.49% | |||
| EBIT | 25.56% | 53.12% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 26.47% | 60.00% | |||
| Normalized Basic EPS | 28.57% | 60.38% | |||
| EPS Diluted | 26.47% | 60.00% | |||
| Normalized Diluted EPS | 28.57% | 60.38% | |||
| Average Basic Shares Outstanding | 0.00% | 15.24% | |||
| Average Diluted Shares Outstanding | 0.00% | 15.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||